XML 27 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Cash flows from operating activities:          
Net loss from continuing operations $ (9,384) $ (4,824) $ (11,101) $ (38,956) $ (28,284)
Adjustment to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization expense 51 65 142 107 86
Non-cash accretion of debt issuance costs 1,078 712 3,054 248 276
Deferred taxes     243 365  
Issuance of common stock as repayment of interest on long-term debt 463 0      
Non-cash stock-based compensation 425 1,278 2,264 1,931 4,666
Litigation settlement payable in common stock     2,650 1,000 0
Fair value of common stock issued in exchange for services 82 0      
Change in fair value of common stock warrants (3,707) (10,520) (22,220) (1,161) (16,556)
Change in fair value of contingent consideration 132 (5,327) (5,047) (509) (170)
Changes in operating assets and liabilities:          
Prepaid expenses and other assets 147 141 892 (245) (1,078)
Litigation settlement insurance recovery 0 21,700 21,700 (21,700) 0
Litigation settlement payable 350 (19,900) (25,000) 24,000 0
Accounts payable (455) (324) (757) (289) (21)
Accrued expenses and other current liabilities (1,658) (589) (50) (3,593) 4,044
Net cash used in continuing operating activities (12,476) (17,588) (33,230) (38,802) (37,037)
Net loss from discontinued operations (10,738) (6,280) (12,448) (24,946) (8,322)
Loss on sale of commercial assets     0 4,549 0
Impairment charge from classification of assets held for sale     0 8,071 0
Changes in operating assets and liabilities attributable to discontinued operations 3,250 (839) 763 2,968 2,490
Net cash used in discontinued operating activities (7,488) (7,119) (11,685) (9,358) (5,832)
Net cash used in operating activities (19,964) (24,707) (44,915) (48,160) (42,869)
Cash flows from investing activities:          
Change in restricted cash (25)   0 (201)  
Cash paid for acquisition of GALE-401     0 0 (2,415)
Cash paid for purchase of equipment and furnishings   (6) (6) (153) (57)
Net cash provided by (used in) continuing investing activities (25) (6) (6) (354) (2,472)
Proceeds received from sale of commercial assets       11,283 0
Selling costs paid for sale of commercial assets   (1,050) (1,050)    
Cash paid for commercial assets     0 (534) (3,056)
Net cash provided by (used in) discontinued investing activities 0 (1,050) (1,050) 10,749 (3,056)
Net cash provided by (used in) investing activities (25) (1,056) (1,056) 10,395 (5,528)
Cash flows from financing activities:          
Net proceeds from issuance of common stock 15,524 20,189 33,534 47,416 10,704
Net proceeds from exercise of stock options   261 261 31 4,342
Proceeds from exercise of warrants 0 233 233 0 10,717
Proceeds from common stock issued in connection with Employee Stock Purchase Plan 5 78 95 309 263
Net proceeds from issuance of long-term debt 0 23,641 23,401 0 0
Change in restricted cash related to debt principal paid in common stock 4,450 0      
Minimum cash covenant on long-term debt 0 (24,000) (17,621) 0 0
Principal payments on long-term debt 0 (4,779) (5,579) (3,911) (1,766)
Net cash provided by financing activities 19,979 15,623 34,324 43,845 24,260
Net increase (decrease) in cash and cash equivalents (10) (10,140) (11,647) 6,080 (24,137)
Cash and cash equivalents at the beginning of period 18,083 29,730 29,730 23,650 47,787
Cash and cash equivalents at end of period 18,073 19,590 18,083 29,730 23,650
Supplemental disclosure of cash flow information:          
Cash received during the periods for interest 83 49 117 18 15
Cash paid during the periods for interest 102 606 636 541 800
Supplemental disclosure of non-cash investing and financing activities:          
Fair value of warrants issued in connection with common stock recorded as cost of equity 10,357 5,590 9,886 10,296 0
Fair value of warrants issued in connection with long-term debt recorded as debt issuance costs     1,139 0 0
Principal and interest repaid through issuance of common stock $ 4,814 0 8,079 0 0
Reclassification of warrant liabilities upon exercise   $ 324 324 0 27,026
Issuance of common stock in settlement of GALE-401 milestone     0 0 6,840
Fair value of shares issued to acquire Zuplenz rights     0 0 2,500
Future obligations for Zuplenz rights included in accrued expenses     $ 0 $ 0 $ 2,716